## S1 Table. Included randomized controlled trials characteristics

Study	Publicatio n status	Baseline severity	N interventi on group	N control group	Patients' characteristics	Intervention	Control	Standard of care (SOC) implemented	Additional interventions
Shouman et al; 2020	Peer- reviewed	Patients exposed to COVID-19 (ambulatory)	228	112	Mean age 38.72 ± 15.94, male 51.3%, HTN 9.5%, DM 7.6%, CKD 1%, asthma 3%, CHD 2.3%	mg twice (second dose at day 3)	No intervention	NR	NR
Chowdhury et al; 2020	Pre-print	Patients with mild to moderate COVID-19 (ambulatory)	63	62	Mean age 33.9 ± 14.1, male 72.4%	lvermectin plus doxycycline 200  µgm/kg single dose + 100 mg BID for 10 days and	HCQ 200 mg daily for 10 days + AZT 500 mg daily for 5 days	NR	NR
Podder et al; 2020	Peer- reviewed	Patients with mild to moderate COVID-19 (ambulatory)	32	30	Mean age 39.16 ± 12.07, male 71%	Ivermectin 200 μgm/kg once + SOC	SOC	Antipyretics, cough suppressants, and capsule doxycycline (100 mg every 12 hours for seven days)	NR
Hashim et al; 2020	Pre-print	Patients with mild to severe COVID-19 (hospitalized)	70	70	Mean age 48.7 ± 8.6, male 52%	lvermectin 200 μgm/kg two or three doses + doxycycline 100 mg twice a day for 5 to 10 days + SOC	SOC	Vitamin C 1000 mg twice/ day and Zinc 75-125 mg/day and Vitamin D3 5000IU/day plus Dexamethasone 6 mg/day or methylprednisolo	Steroids 100%, azithromycin 100%,

								ne 40mg twice per	
								day, if needed	
Mahmud et	Peer-	Patients with	200	200	Mean age 39.6 ± 13.2,	Ivermectin plus	Placebo + SOC	Paracetamol,	NR
al; 2020	reviewed	mild to			male 58.8%, HTN 14%, DM	doxycycline 12 mg		antihistamines,	
		moderate			13%, asthma 5%, CKD 2%	once + 100 mg twice a		cough	
		COVID-19				day for 5 days + SOC		suppressants,	
		(hospitalized)						vitamins,	
								low molecular	
								weight heparin,	
								remdesivir	
								injection	
Elgazzar et al	Pre-print	Patients with	100	100	Mean age 55.2 ± 19.8,	Ivermectin 400	HCQ 800 mg for one	Azithromycin	NR
(mild); <sup>151</sup> 2020		mild to			male 69.5%, HTN 11.5%,	μgm/kg once for 4	day and 400 mf for 4	500mg OD for 6	
		moderate			DM 14.5%, COPD %,	days + SOC and 100	days + SOC	days, Paracetamol	
		COVID-19			asthma 5.5%, CHD 4%	patients assigned to		500mg PRN,	
		(hospitalized)						vitamin C 1gm	
								OD, Zinc 50 mg	
								OD, Lactoferrin	
								100mg sachets	
								BID , Acetylcystein	
								200mg t.d.s &	
								prophylactic or	
								therapeutic	
								anticoagulation if	
								D-dimer > 1000	
Elgazzar et al	Pre-print	Patients with	100	100	Mean age 39.6 ± 13.2,	Ivermectin 400	HCQ 800 mg for one	Azithromycin	NR
(severe);151		severe			male 58.8%, HTN 14%, DM	μgm/kg once for 4	day and 400 mg for 9	500mg OD for 6	
2020		COVID-19			13%, asthma 5%, CKD 2%	days + SOC	days + SOC	days, Paracetamol	
		(hospitalized)						500mg PRN,	

								vitamin C 1gm	
								OD, Zinc 50 mg	
								OD, Lactoferrin	
								100mg sachets	
								BID , Acetylcystein	
								200mg sachets	
								t.d.s , prophylactic	
								or therapeutic	
								anticoagulation if	
								D-dimer > 1000	
								and systemic	
								steroids	
Elgazzar et al	Pre-print	People	100	100	Mean age: 57.2, male	Ivermectin 400	SOC	Personal	NR
(prophylaxis); <sup>1</sup>	Pre-print	exposed to	100	100	73.5%, DM 17%, HTN	µgm/kg twice (second	300	protective	INK
<sup>51</sup> 2020		SARS-COV-2			14.5%, CHD 2%, asthma	dose after one week) +		measures (PPM):	
2020		infection			4.5%	SOC		hand hygiene,	
		(ambulatory)			4.5%	300		social distance	
		(allibulatory)							
								measures, avoiding touching	
								the eyes, nose,	
								and, face masks,	
								gloves, respiratory	
								etiquette and self-	
								isolation	
Krolewiecki et	Peer-	Patients with	30	15	Mean age 40.9 ± 12.5,	Ivermectin 0.6 mg/kg	SOC	NR	NR
al; <sup>152</sup> 2020	reviewed	mild to			male 56%, HTN 13.3%, DM	for 5 days + SOC			
		moderate			15.5%, COPD and asthma				
		COVID-19			11.1%, obesity 38%				
l J									
		(hospitalized)							

Niaee et al;153	Pre-print	Patients with	120	60	Median age 56 ± 20, male	Ivermectin 200	SOC or placebo +	Hydroxychloroqui	NR
2020		mild to			50%	microg/kg once + SOC	SOC	ne 200mg/kg	
		severe				or Ivermectin 200		twice per day	
		COVID-19				microg/kg daily for 3			
		(hospitalized)				days + SOC or			
						Ivermectin 400			
						microg/kg once + SOC			
						or Ivermectin 400			
						microg/kg once + 200			
						microg/kg daily for 2			
						days + SOC			
Ahmed et	Peer-	Patients with	24	24	Mean age 42, male 46%,	Ivermectin 12 mg a	placebo	NR	NR
al; <sup>154</sup> 2020	reviewed	mild to				day for 5 days or			
		moderate				ivermectin 12 mg a			
		COVID-19				day for 5 days +			
		(hospitalized				doxycycline 100 mg			
		patients)				and			
Chaccour et	Peer-	Patients with	12	12	Median age 26, male 50%,	Ivermectin 400	placebo	NR	NR
al; 2020	reviewed	mild COVID-				microg/kg			
		19 (early							
		within 3 days							
		of onset,							
		ambulatory)							
Chachar et	Peer-	Patients with	25	25	Mean age 41.8±15.7, male	Ivermectin 36mg once	soc	NR	NR
al; <sup>156</sup> 2020	reviewed	mild COVID-			62%, HTN 26%, DM 40%,	+ SOC			
		19			obesity 12%, CHD 8%				
		(ambulatory)							
Babalola et	Peer-	Patients with	21	20	Mean age 44.1 ± 14.7,	Ivermectin 12 mg a	lopinavir-ritonavir +	Zinc 62%	Steroids 3.2%,
al; <sup>157</sup> 2020	reviewed	mild to			male 69.4%, HTN 14.5%,	week + SOC, or	soc		

		severe COVID-19			DM 3.2%	ivermectin 24 mg a week for 2 weeks +			
		(ambulatory				SOC			
		and							
		hospitalized)							
Kirti et al;	Pre-print	Patients with	55	57	Mean age 52.5 ± 14.7,	Ivermectin 24mg	Placebo + SOC	Steroids 100%,	remdesivir 20.5%,
2020		mild to			male 72.3%, HTN 34.8%,	divided in two doses +		HCQ 100%	tocilizumab
		moderate			DM 35.7%, COPD 0.9%,	SOC			6.3%,
		COVID-19			asthma 0.9%, CHD 8.9%,				convalescent
		(hospitalized)			CKD 2.7%, cerebrovascular				plasma 13.4%
					disease 0%, cancer 5.4%				
Chahla et al;	Pre-print	People	117	117	Median age 38 ± 12.5,	Ivermectin + iota-	SOC	Standard	NR
2020		exposed to			male 42.7%, HTN 9%, DM	carrageenan 12mg a		biosecurity care	
		SARS-COV-2			7.3%, CKD 2.1%, obesity	week + 6 sprays a day		and personal	
		infection			11.9%	for 4 weeks + SOC and		protective	
		(ambulatory)						equipment (PPE)	
Mohan et	Pre-print	Patients with	100	52	Mean age 35.3 ± 10.4,	Ivermectin 12 mg	Placebo + SOC	NR	Steroids 14.4%,
al; <sup>159</sup> 2020		mild to			male 88.8%, HTN 11.2%,	(equivalent to 200			remdesivir 1.6%,
		moderate			DM 8.8%, CHD 0.8%	μg/kg) elixir + SOC or			hydroxychloroqui
		COVID-19				Ivermectin 24 mg			ne 4%,
		(hospitalized)				(equivalent to 400			azithromycin
						μg/kg) + SOC			11.2%
Samaha et	Peer-	Patients with	50	50	Mean age: 31.78 ± 7.85,	Ivermectin 0.2 mg/kg	SOC	Zinc (30–50	NR
al; <sup>159</sup> 2020	reviewed	asymptomati			male 50%, HTN 8%, DM	once + SOC		mg/day) and	
		c SARS-COV-2			6%			Vitamin C (500 mg	
		infection						BID, twice daily)	
		(ambulatory)						supplements	

Bukhari et al; <sup>160</sup> 2020	Pre-print	Patients with mild to moderate COVID-19 (hospitalized)	50	50	Mean age: 40.6, males 73%, HTN 14%, DM 11.6%, CHD 5.8%	Ivermectin 12 mg once + SOC	SOC	vitamin C 500 mg once daily, vitamin D3 200,000 IU once weekly, Paracetamol 500 mg if necessary.	NR
Okumus et al; <sup>161</sup> 2021	Peer- reviewed	Patients with severe COVID-19 (hospitalized)	36	30	Mean age 62 ± 12, male 60.6%, HTN 45%, DM 31.6%, COPD 15%, CHD 21.6%, cancer 1.6%	Ivermectin 0.2 mg/kg for 5 day + SOC	SOC	Hydroxychloroqui ne (2x400mg loading dose followed by 2x200mg for 5 days), favipiravir (2x1600mg loading dose followed by 2x600mg maintenance dose, po, total 5 days	NR
Beltran- Gonzalez et al; <sup>126</sup> 2021	Pre-print	Patients with moderate to severe COVID-19 (hospitalized)	36	37	Mean age 54 ± 23.5, male 46.8%, HTN 19.1%, DM 9.6%, COPD 1%, CHD 7.4%, cerebrovascular disease 5.3%	Ivermectin 12-18 mg once	Placebo	dexamethasone, 6 mg IV every 24 hours, unfractioned heparin	Steroids 9.6%, lopinavir-ritonavir 44.7%
Lopez-Medina et al; <sup>162</sup> 2021	Peer- reviewed	Patients with mild COVID- 19 (ambulatory)	238	238	Median age 37 ± 19, male 42%, HTN 13.4%, DM 5.5%, COPD 3%, CHD 1.7%, cancer %, obesity 18.9%	Ivermectin 300 μg/kg a day for 5 days	Placebo	NR	Steroids 4.5%
Bermejo	Peer-	Patients with	53	54	Mean age 53.4 ± 15.6,	Ivermectin 42mg	CQ 900 mg for 1 day,	Azithromycin (500	Steroids 98%

Galan et al; <sup>128</sup>	reviewed	severe to			male 58.2%, HTN 43.4%,		and 450 mg for 4	mg 1× for 5 days)	
	revieweu						· ·		
2021		critical			DM 28.1%, COPD 5.3%,		days or HCQ 800 mg	and ceftriaxone (1	
		COVID-19			CKD 2.5%, cancer 3%,		for 1 day and 400 mg	g 2× for 7 days).	
		(hospitalized)			obesity 37.5%		for 4 days	Oseltamivir (75	
								mg 2× for 5 days)	
								Proportions NR	
								Steroids 98%	
Pott-Junior et	Peer-	Patients with	28	7	Mean age 49.4 ± 14.6,	Ivermectin 100 + SOC	SOC	NR.	Steroids 32.3%
al; <sup>163</sup> 2021	reviewed	mild to			male 45.2%	or ivermectin 200			
		severe				mc/kg + SOC or			
		COVID-19				ivermectin 400 mcg/kg			
		(hospitalized)				+ SOC			
Kishoria et	Peer-	Patients with	19	16	Mean age 38 ±, male 66%	Ivermectin 12mg	SOC	Hydroxychloroqui	NR
al; <sup>164</sup> 2021	reviewed	asymptomati				single dose + SOC		ne 400 mg twice a	
		c to mild						day, Paracetamol	
		COVID-19						500mg as	
		(ambulatory)						required, Vitamin	
								C 1 tab twice a	
								day; for five days	
	_								
Seet et al;129;	Peer-	People	709	633	Mean age 33, male 100%,	Ivermectin 12mg once	vitamin C	NR	NR
2021	reviewed	exposed to			hypertension 0.8%,				
		SARS-COV-2			diabetes 0.3%				
		infection.							
		(ambulatory)							
Shahbaznejad	Peer-	Patients with	35	38	Mean age 46.4 ± 22.5,	Ivermectin 0.2 mg/kg	soc	Chloroquine	NR
et al; 2020	reviewed	moderate to			male 52.2%	once + SOC		75.4%, lopinavir-	
		critical						ritonavir 79.7%,	
		COVID-19						antibiotics 89.8%	

		(hospitalized)							
Abd-Elsalam S et al.; 2021	Peer- reviewed	Patients with mild to moderate COVID-19 infection (hospitalized)	82	82	Mean age 40.9 ± 16.5, male 50%, HTN 20%, DM 16%	Ivermectin 12 mg a day for 3 days + SOC	SOC	Paracetamol, oxygen, fluids (according to the condition of the patient), empiric antibiotic, oseltam ivir if needed (75 mg/12 h for 5 days)	NR
Biber et al; 2021	Pre-print	Patients with mild recent onset COVID19 (ambulatory)	47	42	Mean age 35 ± 19, male 78.4%	Ivermectin 48 to 55 mg administered for three days + SOC	SOC	NR	NR
Faisal et al; 2021	Peer- reviewed	Patients with mild COVID-19 (ambulatory)	50	50	Mean age 46 ± 3, male 80%	Ivermectin 12 mg a day for 5 days + SOC	SOC	Paracetamol (500mg if needed), Vit C (500mg once a day for 15 days), zinc (20mg twice a day for 15 days) and Vit D (injection PO 200,000units once) supplements.	NR
Vallejos et al; 2021	Peer-	Patients with mild	250	251	Mean age 42.5 ± 15.5, male 52.7%, hypertension	Ivermectin 24 to 36mg (according to baseline	SOC	NR	NR

reviewed COVID-19 (ambulatory)	23.8%, diabetes 9.6%, COPD 2.8%, asthma 7.2%, CHD 1.8%, cancer 1.2%	bodyweight) divided in 2 doses		
--------------------------------	---	-----------------------------------	--	--

SOC: standard of care; NR: not registered; HTN: arterial blood hypertension; DM: diabetes mellitus; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; CHD: coronary heart disease; CQ: chloroquine; HCQ: hydroxychloroquine.